2019

Apr 13, 2019View PDF

IND approval for the MARCH trial with respect to ATG-010 (selinexor) was received in mainland China

Our Group completed the Series B financing with an aggregate amount of approximately US$120 million

IND approval for the SEARCH trial with respect to ATG-010 (selinexor) was received in mainland China

Our Regulatory Affairs Center commenced operation in Beijing

Our Group won the championship of the 8th China Innovation & Entrepreneurship Competition

We and AstraZeneca established cooperation to develop, manufacture and commercialize ATG-017 worldwide

IND approval for the TEACH trial with respect to ATG-019 was received in Taiwan

ATG-010 was selected into National Science and Technology Major Project